Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma

European Journal of Medicinal Chemistry
2010.0

Abstract

The first glucuronide prodrug of the hedgehog signaling inhibitor cyclopamine was synthesized. The carbamoyl derivatisation of cyclopamine significantly decreased its toxicity towards the U87 human glioblastoma cell line. However, when the prodrug was incubated with beta-glucuronidase in the culture media, the active drug was efficiently released thereby restoring its anti-proliferative activity.

Knowledge Graph

Similar Paper

Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma
European Journal of Medicinal Chemistry 2010.0
Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy
European Journal of Medicinal Chemistry 2013.0
Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer
Bioorganic & Medicinal Chemistry 2008.0
Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy
Journal of Medicinal Chemistry 2008.0
Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside for application in selective prodrug chemotherapy
Bioorganic & Medicinal Chemistry Letters 2007.0
Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
Journal of Medicinal Chemistry 1999.0
Synthesis and anticancer activity studies of cyclopamine derivatives
Bioorganic & Medicinal Chemistry Letters 2008.0
Cancer chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategy
Bioorganic & Medicinal Chemistry Letters 2003.0
Semisynthetic Cyclopamine Analogues as Potent and Orally Bioavailable Hedgehog Pathway Antagonists
Journal of Medicinal Chemistry 2008.0
Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin
Journal of Medicinal Chemistry 2012.0